You are here

Development of an Antigen Capture Assay for Babesia microti

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI108006-01A1
Agency Tracking Number: R41AI108006
Amount: $586,079.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-124
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-06-11
Award End Date (Contract End Date): 2016-05-31
Small Business Information
East Setauket, NY 11733-3728
United States
DUNS: 140704532
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (914) 493-7237
Business Contact
Phone: (516) 662-3287
Research Institution
VALHALLA, NY 10595-1524
United States

 Nonprofit college or university

DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor blood for B microti This inability to prevent Babesia contamination of the US blood supply has resulted in transfusion transmitted Babesia emerging as the leading cause of death due to microbial contamination of US blood supplies In this phase STTR application we will focus on developing monoclonal antibodies mAbs for a rapid antigen capture assay that is both sensitive and specific for the detection of B microti antigens in human blood This assay will fill the current gap in the ability to protect the US blood supply against B microti infected blood Very few antigenic peptides have been identified in B microti that could be used in an antigen capture assay Consequently in Aim we will use a novel procedure to generate mAbs to the full spectrum of Babesia antigens generated during infection and identify peptides recognized by the mAbs In Aim we will express these Babesia antigens in an innovative Toxoplasma expression system to retain conformational in addition to linear epitopes in the proteins that may be important for mAb recognition This expression system will be used to purify a consistent amount of Babesia antigens for use in downstream assay development and as standards for our prototype assay In Aim we will identify non interfering pairs of monoclonal antibodies to be used as a capture and reporter for each antigen to generate a prototype antigen capture assay for Babesia PUBLIC HEALTH RELEVANCE Babesiosis has become the most commonly reported infection in the US associated with contaminated blood transfusion In infants the elderly immunocompromised or splenectomized individuals infection can cause an array of severe manifestations including substantial hemolysis disseminated intravascular coagulation multiple organ failure acute respiratory distress syndrome renal and hepatic failure myocardial infarction and death with the mortality rate of transfusion acquired infection being reported as high as There is currently no FDA licensed method to screen donated blood for Babesia This application focuses on the creation of a rapid antigen capture assay that is both sensitive and specific for the detection of Babesia antigens in human blood which is critically needed to insure the safety of the US blood supply

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government